| AVS 62nd International Symposium & Exhibition | |
| Surface Modification of Materials by Plasmas for Medical Purposes Focus Topic | Thursday Sessions |
| Session SM+AS+BI+PS-ThM |
| Session: | Plasma Processing of Biomaterials |
| Presenter: | Jean-Michel Pouvesle, GREMI CNRS/Université d'Orléans, France |
| Authors: | J.-M. Pouvesle, GREMI CNRS/Université d'Orléans, France G. Collet, CNRS E. Robert, GREMI CNRS/Université d'Orléans, France L. Ridou, CNRS-CBM, France S. Dozias, GREMI CNRS/Université d'Orléans, France T. Darny, GREMI CNRS/Université d'Orléans, France B. El Hafni-Rahbi, CNRS-CBM, France C. Kieda, CNRS-CBM, France |
| Correspondent: | Click to Email |
The last decade has seen an impressive increase of the research dedicated to the biomedical applications of low temperature Non Thermal Plasmas (ltNTP), especially with plasma sources working at atmospheric pressure. Medical applications of ltNTP now concern a very wide range of domains including cancer treatment. The antitumor effect of ltNTP has been clearly shown in vivo on murine modelswith various cancer types (bladder, colon, glioblastoma, melanoma, ovary, pancreas). Although the involved mechanisms are far from being fully understood, the therapeutic effect is now totally admitted and the first clinical study (head and neck) has been reported [1]. In case of plasma jet experiments, the observed effect are most of the time attributed to the very rich chemistry generated by the interaction of the rare gas plasma plume with the surrounding environment constituted either from the ambient air, or this latter in complex interaction with liquids at the interface with the targeted organ. Our recent experiments performed on tissue oxygenation[2] or breast cancer treatments on immunocompetent mice [3] lead to the conclusion that probably the involved chemistry couldn’t, alone, completely allow describing the observed phenomena. This, especially under very soft treatment conditions, is suggesting possible triggering of some immune system chain processes and also possible modifications in the microenvironment of tissue and tumors. In this context, there is still an unknown role of the electric field associated with the ionization front or generated in the environment of the plasma plume tip. Taking into consideration the recent vessel normalization based-cancer treatment, the ltNTP effect should be further investigated in view of blood vessels structure and function (blood flow) as well as tumor hypoxia compensation to confirm a possible ltNTP-based adjuvant approach for cancer treatments. These results suggest new ways, especially combined therapy, to consider the plasma and its therapeutic delivery in ltNTP-based tumor therapy. In this talk, after a presentation of the context and the plasma devices, we will go through the specific case of cancer treatment with what have been already demonstrated in vitro and in vivo, what can be directly linked with the produced discharges, including recent results on electric field measurements in plasma biological application conditions.
This work is supported by the APR Region Centre PLASMEDNORM.
References:
[1] H.R. Metelmann et al Clin. Plas Med. Doi.org/10.1016/j.cpme.2015.02.001
[2] G. Collet et al PSST 23 (2014) 012005
[3] G. Collet et al ICPM5, May 18-23, 2014, Nara (Japan)